Sound Bioventures
Venture capitalMalmö · Seed–Late Stage · 9 people tracked
Investment thesis
Sound Bioventures backs private biopharmaceutical companies that are about to enter or already in clinical stages, focusing on specialty therapeutic areas and the development of new medicines. The firm invests internationally across Europe and the USA, having originated as a Danish-Swedish partnership rooted in the Greater Copenhagen 'Medicon Valley' region. It positions itself as a straightforward, transparent and long-term-oriented co-investor that prioritizes doing what is right for its portfolio companies.
Source: firm website, verified Aug 3, 2026.
Team · 9 people
from the firm's website & public directories
What they invest in
from 12 of 24 portfolio companiesBiotech ×11Healthtech ×4Media & Entertainment ×4Medical Devices ×3Data & Infrastructure ×1Deep Tech ×1Enterprise Software ×1Fintech ×1
HQs:United States×3France×1
Investments · 24 tracked
founders shown can be your intro pathAbolerIS Pharma develops therapeutic approaches that regulate the immune system by inducing immune tolerance while preserving useful immune responses, targeting inflammatory, autoimmune, and degenerative diseases.
BiotechHealthtech
Ignacio Anegon(Co-founder, Senior Consultant & SAB Member)Carole Guillonneau(Co-founder & Head of Research)François-Xavier Hubert(Co-founder, Past President & Board Member)
Artax Biopharma is a Phase 2 clinical-stage biotechnology company developing first-in-class oral small-molecule Nck modulators that target T cell receptor Signal 1 activation to treat autoimmune diseases without causing immunosuppression.
BiotechHealthtechCambridge, US
Joe Suarez(Executive Officer)Maria Nichol(Executive Officer)Robert W. Armstrong, Ph.D.(Executive Officer, Director)Damia Tormo(President, CEO, Treasurer and Founder)Henri Termeer(Director)Peter B. Finn(Secretary)
Clinical-stage biotech developing medicines through modulation of microRNAs; lead compound is ATX-01.
Arthex Biotech develops an investigational anti-miR therapeutic targeting an upregulated miRNA for the treatment of myotonic dystrophy, aiming to address the root cause of the disease.
BiotechMedical Devices
BioCentury provides business intelligence, market analysis, and networking services for biotech and pharmaceutical industry leaders.
BiotechData & InfrastructureEnterprise SoftwareDurham, US
Pieter Burger(Executive Officer, Director)Thomas Kaiser(Executive Officer, Director)
BoardChristopher Meldrum(Executive Officer, Director)John Hamer(Director)Dennis Langer(Director)
Biotech Finances is a French-language news and analysis publication covering the biotech, pharma and medtech industries, focusing on financing, mergers and acquisitions, clinical developments and listed biotech valuations.
BiotechMedia & Entertainment
BioWorld publishes news and data on the biopharmaceutical and drug development industry, covering topics such as clinical trials, licensing deals, oncology pipelines, and gene therapies.
BiotechMedia & Entertainment
Born2Invest is an online financial news publication covering markets, investing, crowdfunding, biotechnology, and cryptocurrency for a general investor audience.
FintechMedia & Entertainment
Clinical-stage company developing ophthalmology therapies; lead program Danegaptide, an oral drug for diabetic retinopathy.
Preclinical-stage company developing next-generation gamma delta T cell engagers for solid and haematological malignancies.
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
A media outlet covering the European biotechnology industry, featuring news and event coverage such as the BIOSPAIN biotech conference.
BiotechMedia & Entertainment
Nephrodi is a biotechnology company developing treatments for kidney conditions, including the rare disease Nephrogenic Diabetes Insipidus (NDI).
BiotechHealthtechMedical DevicesSeattle, US
Fred Callori(Director)Chris Garabedian(Director)Donna See(Director)Jeff M. Sands, M.D.(Executive Officer)Rachael Hagan(President & Chief Executive Officer)Jeff Sands
Preclinical-stage company developing therapeutics for neurodegenerative diseases including Huntington's, Parkinson's and frontotemporal dementia.
Theolytics develops oncolytic adenovirus-based immunotherapies to overcome the tumor microenvironment barriers in solid cancers.
BiotechDeep TechMedical Devices
Frequently asked questions
- What stage does Sound Bioventures invest at?
- Sound Bioventures invests at the Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Sound Bioventures focus on?
- Sound Bioventures focuses on Biotech, Healthtech, Medical Devices.
- Where is Sound Bioventures located?
- Sound Bioventures is headquartered in Malmö, SE.
- Does Sound Bioventures lead rounds?
- Yes, Sound Bioventures leads investment rounds.
Images
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Capricorn Venture Partners is a European investment firm managing several thematic funds across growth capital, healthcare, and cleantech, as well as a combined private/quoted investment vehicle.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Korea Investment Partners is a South Korea-based venture capital firm that invests across multiple stages from early-stage startups through growth and buyout transactions, including venture debt and mezzanine financing. The firm operates across venture capital, middle market, and growth equity investment categories.